Bispecific Antibodies Revolutionize Cancer Therapy: 15 FDA-Approved, Over 600 in Clinical Trials as T-Cell Engagers

August 30, 2026

BroadPharm USA

Overview

Bispecific antibodies (BsAbs) are engineered to simultaneously bind two different antigens or epitopes, offering superior disease target recognition and biological effect modulation compared to conventional monoclonal antibodies. Primarily used in cancer treatment, particularly as T-cell engagers to redirect T cells to tumor cells, 15 BsAbs are currently FDA-approved, with over 600 more in clinical trials globally. This burgeoning field is opening new frontiers in oncology.

In Depth

Key Findings

Bispecific antibodies (BsAbs) represent a groundbreaking class of therapeutics designed to simultaneously engage two distinct antigens or epitopes, offering significant advantages over traditional monoclonal antibodies in targeted disease recognition and the modulation of biological effects. Their most impactful application is currently in cancer therapy, where they function as potent T-cell engagers, precisely redirecting the patient’s immune cells to tumor targets to induce cytotoxic responses.

Technical & Clinical Details

Mechanism of Action: BsAbs typically feature two antigen-binding sites, allowing them to bridge immune effector cells (e.g., T cells via CD3) with tumor cells (via a tumor-specific antigen like CD19 or BCMA). This physical proximity facilitates the activation of the immune cell and directs its cytotoxic machinery against the cancer cell, thereby overcoming tumor immune evasion mechanisms.
FDA Approvals & Pipeline: To date, 15 BsAbs have received FDA approval for various hematologic malignancies, including blinatumomab for B-cell acute lymphoblastic leukemia and teclistamab for multiple myeloma. These approved therapies have demonstrated remarkable clinical efficacy in specific patient populations, often those refractory to conventional treatments. Globally, over 600 BsAbs are currently undergoing clinical evaluation across diverse oncology and other therapeutic indications, highlighting robust research and development activity in the field.
Clinical Efficacy: Approved BsAbs have shown deep and durable responses in patients, often achieving high response rates in previously difficult-to-treat cancers. Their ability to activate a patient’s own immune system makes them a powerful tool in the precision medicine arsenal.

Background & Context

Monoclonal antibodies, while transformative, are limited by their single-target specificity. BsAbs overcome this by engaging multiple targets, offering enhanced potency and specificity, particularly in the complex tumor microenvironment. This bifunctional binding enables more effective immune cell recruitment and tumor cell killing, positioning BsAbs as a critical component in the evolution of cancer immunotherapy. The pharmaceutical industry views BsAbs as a strategic area for investment, driving significant efforts in novel design, engineering, and manufacturing optimization.

Strategic Significance & Outlook

The success of BsAbs in oncology is paving the way for their exploration in other disease areas, including infectious diseases and autoimmune disorders. Future research will focus on improving safety profiles, enhancing target specificity, and optimizing drug delivery. Furthermore, the development of BsAb-drug conjugates (ADCs) and BsAb-gene therapy constructs represents an exciting frontier, promising even more potent and targeted therapies. As the technology matures, BsAbs are expected to solidify their role as a cornerstone of next-generation biopharmaceuticals, offering new hope for patients with high unmet medical needs.

Source: https://broadpharm.com/blog/what-is-bispecific-antibody

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.